Found: 24
Select item for more details and to access through your institution.
Dimethyl Fumarate.
- Published in:
- International Journal of MS Care, 2017, v. 19, n. 2, p. 74, doi. 10.7224/1537-2073.2015-086
- By:
- Publication type:
- Article
Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate.
- Published in:
- International Journal of MS Care, 2015, v. 17, n. 5, p. 236, doi. 10.7224/1537-2073.2014-069
- By:
- Publication type:
- Article
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 2, p. 253, doi. 10.1177/1352458516649037
- By:
- Publication type:
- Article
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS).
- Published in:
- Multiple Sclerosis Journal, 2015, v. 21, n. 1, p. 57, doi. 10.1177/1352458514537013
- By:
- Publication type:
- Article
Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing–remitting multiple sclerosis: findings from the CONFIRM study.
- Published in:
- Multiple Sclerosis Journal, 2014, v. 20, n. 2, p. 253, doi. 10.1177/1352458513507818
- By:
- Publication type:
- Article
Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2011, v. 17, n. 8, p. 970, doi. 10.1177/1352458511399611
- By:
- Publication type:
- Article
Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials.
- Published in:
- Annals of Clinical & Translational Neurology, 2015, v. 2, n. 2, p. 103, doi. 10.1002/acn3.148
- By:
- Publication type:
- Article
Prolactin Stimulates Proliferation of Cultured Human Keratinocytes.
- Published in:
- Journal of Investigative Dermatology, 1993, v. 101, n. 3, p. 275, doi. 10.1111/1523-1747.ep12365203
- By:
- Publication type:
- Article
Primary Physician or Primary Care Physician?
- Published in:
- 2019
- By:
- Publication type:
- letter
Gene Farley tribute.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Gene Farley Tribute.
- Published in:
- Family Medicine, 2014, v. 46, n. 5, p. 391
- By:
- Publication type:
- Article
Development of a fixed module repertoire for the analysis and interpretation of blood transcriptome data.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-24584-w
- By:
- Publication type:
- Article
Natalizumab: benefit outweighs risk in selected patients with multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2008, v. 1, n. 3, p. 151, doi. 10.1177/1756285608099124
- By:
- Publication type:
- Article
An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes.
- Published in:
- Neurology & Therapy, 2019, v. 8, n. 1, p. 109, doi. 10.1007/s40120-019-0127-2
- By:
- Publication type:
- Article
Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study.
- Published in:
- Neurology & Therapy, 2015, v. 4, n. 2, p. 137, doi. 10.1007/s40120-015-0037-x
- By:
- Publication type:
- Article
Multiple sclerosis patients’ benefit-risk preferences: Serious adverse event risks versus treatment efficacy.
- Published in:
- Journal of Neurology, 2009, v. 256, n. 4, p. 554, doi. 10.1007/s00415-009-0084-2
- By:
- Publication type:
- Article
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
- Published in:
- Journal of Neurology, 2009, v. 256, n. 3, p. 405, doi. 10.1007/s00415-009-0093-1
- By:
- Publication type:
- Article
A Clinical Therapeutic Trial of Cyclosporine in Myasthenia Gravisa.
- Published in:
- Annals of the New York Academy of Sciences, 1993, v. 681, n. 1, p. 539, doi. 10.1111/j.1749-6632.1993.tb22937.x
- By:
- Publication type:
- Article
A Double-Blind Randomized Placebo-Controlled Trial to Assess the Safety and Efficacy of Cyclosporin A in the Treatment of Myasthenia Gravis<sup>a</sup>.
- Published in:
- Annals of the New York Academy of Sciences, 1987, v. 505, n. 1, p. 854, doi. 10.1111/j.1749-6632.1987.tb51391.x
- By:
- Publication type:
- Article
Health-related quality of life in multiple sclerosis: effects of natalizumab.
- Published in:
- Annals of Neurology, 2007, v. 62, n. 4, p. 335, doi. 10.1002/ana.21163
- By:
- Publication type:
- Article
Immune surveillance in multiple sclerosis patients treated with natalizumab.
- Published in:
- Annals of Neurology, 2006, v. 59, n. 5, p. 743, doi. 10.1002/ana.20858
- By:
- Publication type:
- Article
Quality of Life of Patients Enrolled in MSTRAC: A Registry of Multiple Sclerosis Treatment and Care.
- Published in:
- Multiple Sclerosis (13524585), 2000, v. 6, n. 6, p. 413
- By:
- Publication type:
- Article
Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
- Published in:
- European Journal of Neurology, 2017, v. 24, n. 5, p. 726, doi. 10.1111/ene.13272
- By:
- Publication type:
- Article